Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (September 2020)
17 slides from Moleculin Biotech's investor presentation, Sep 1, 2020
Slide 1: Developing ground-breaking therapies for highly resistant cancers and viruses
ss F wv Moleculin Developing ground-breaking therapies for highly resistant cancers and viruses September 1, 2020 Public Presentation (Nasdaq: MBRX)
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements, The words “believe;
Slide 3: Highly Experienced Leadership
Slide 4: Executive Management Team
Executive Management Tea ; 4) cy er) Walter Klemp, Chairman, President & CEO Don Picker, PhD Chief Science Officer Jonathan P. Foster, CPA, CCMA EvP & CFO Robert Shepard, ‘MD, FACP. Chief Medical Officer ‘SandraSilberman, MD & PhD Chief Medical Officer - New Products Selected Prior Experience solito
Slide 5: Science Advisory Board
Science Advisory Board 1 Waldemar Priebe, PhO James MDAnderson ‘Ceneex Center rl Pancreatic ‘Abbruzzese, MD DANA-FARBER Duke University School of Medicine Hematology Elihu Estey, ) MD FRED HUTCH anstorens Marty Tallman, MD Memorial Sloan Kettering or Jorge Cortes, py NEW ENGLAND. oun Reawe seoncia [
Slide 6: World class collaboration
World class collaboration Highly experienced team Exclusive IP/Fast Track Non-cardiotoxic anthracycline STATS Inhibitor Antimetaboltes — sancers and viruses
Slide 7: Antimetabolites / Glycosylation Inhibitor
Antimetabolites / Glycosylation Inhibitor AT3 inhibitor Prodrug of glucose decoy enables drug-like properties pat Disruption of metabolisms - relevant to certain cancers and viruses P1066 Potential for Drug mbination Therapi SMolecutin
Slide 8: Leading Partnerships, Collaborations
ading Partnerships, Collaborations laborations sig expand and increase our knowledgebase REGA INSTITUTE KU LEUVEN 1, Dominique Schols of the Rega institute has joined the Molecalin Science Advisory ‘Anmamycin AML trial in EU, Sublcenses for co-development. collaborations evelopment. W1220 Phase 1 tr
Slide 9: Development Pipeline – Internal
evelopment Fipeline — Interne Phase 1 Activity Phase 2 wep‘. Anderson a Antimetabolites/ Glycosylation Inhibitor wen‘. SMoleculin
Slide 10: Development Pipeline
velopmen Antimetabolite osylation Inhibitor Ipeline XTe Phase 1 Activity Phase 2 MDAnderson Ether Cater (pp Mwocunic EMORY MDAnderson Encer Cenee wen'« 10
Slide 11: Key Developments
Key Developments Next Generation Anthracycline - Annamy Trials) + Positive interim safety and efficacy data in US and Europe AML Trials 5% efficacy in 11 relapsed AML patients treated atfor above 120 may (1.CRi, 3 PRs, 1 678); clearing circulating blasts + No evidence of cardiotoxicity + U.S. conclu
Slide 12: Key Developments
Key Developments QS Molecutin A ‘SubmitiNCTA forCOVID-19 12
Slide 13: Additional Potential 2020 Value Inflection Points
Additional Potential 2020 Value Inflection Points STATS Inhibitors MDA WP1066 and Radiation GBM Trial Approved & Trial Begins Emory Pediatric Brain Tumor Phase 1 Begins File WP1220 CTCL Phase 2 Trial IND/CTA or Strategic Partner QS Moleculin
Slide 14: Financial Review
al Ri evie ew
Slide 15: Financial Statement Summary
In thousands, except for share and per share Forthe Year Ended outstanding 12034 (Unaudited) ‘Statement of Operations Data Revenue a Research and development sit019 General and admistatve and depreciation 6st Loss rom operations (aTs24) Net oss (13208) Net oss per common share —basic and died $032)
Slide 16: Various Sources of Financing
Various Sources of Financin Opportunistic Approach * Approx. $20 million raised 2019; $17 million YTD 2020 * Three analysts have reported on MBRX— Roth, Maxim, & Opco * Overnight and intraday deals + $15 million ATM - Opco * Equity Line - Lincoln Park Capital * Successful out-licensing of technology
Slide 17: World class collaboration
World class collaboration Highly experienced team Exclusive IP/Fast Track Non-cardiotoxic anthracycline STATS Inhibitor Antimetaboltes — sancers and viruses
Moleculin Biotech — Investor Presentation (September 2020) on 6ix